JO3126B1 - مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 - Google Patents

مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1

Info

Publication number
JO3126B1
JO3126B1 JOP/2008/0435A JOP20080435A JO3126B1 JO 3126 B1 JO3126 B1 JO 3126B1 JO P20080435 A JOP20080435 A JO P20080435A JO 3126 B1 JO3126 B1 JO 3126B1
Authority
JO
Jordan
Prior art keywords
nucleoside transporter
equilibrative nucleoside
compounds
inhibitors
enti
Prior art date
Application number
JOP/2008/0435A
Other languages
English (en)
Inventor
Jean- Paul Rene Marie Andre Bosmans
Serge Maria Aloysius Pieters
Didier Jean-Claude Berthelot
Cleyn Michel Anna Jozef De
Bie Maria Pieter Verbist
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3126B1 publication Critical patent/JO3126B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ( COMPOUNDS) جديدة من الصيغه ( I) لها خواص تثبيط ( INHIBITING) ENTI ناقل ( TRANSPORTER) NUCLEOSIDE متوازن، بتركيبات دوائية ( PHRMAEUTICAL COMPOSITIONS) تشمل هذه المركبات بعمليات كيميائية ( CHEMICAL PROCESSES) من اجل تحضير هذه المركبات وباستخدامها في معالجة امراض مرتبطة بتثبيط مستقبلات ( RECEPTORS) ENTI في الحيوانات، على وجة الخصوص ادميين
JOP/2008/0435A 2007-11-14 2008-10-07 مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 JO3126B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120630 2007-11-14

Publications (1)

Publication Number Publication Date
JO3126B1 true JO3126B1 (ar) 2017-09-20

Family

ID=39145373

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0435A JO3126B1 (ar) 2007-11-14 2008-10-07 مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1

Country Status (17)

Country Link
US (1) US8263592B2 (ar)
EP (1) EP2209790B1 (ar)
JP (1) JP5369108B2 (ar)
KR (1) KR101598136B1 (ar)
CN (1) CN101855224B (ar)
AR (1) AR069304A1 (ar)
AU (1) AU2008322960B2 (ar)
BR (1) BRPI0820642B1 (ar)
CA (1) CA2704423C (ar)
CL (1) CL2008003383A1 (ar)
EA (1) EA017215B1 (ar)
ES (1) ES2569511T3 (ar)
IL (1) IL205710A (ar)
JO (1) JO3126B1 (ar)
PA (1) PA8803401A1 (ar)
TW (1) TWI437000B (ar)
WO (1) WO2009062990A2 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
EP3371174B1 (en) * 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
CN105802999B (zh) * 2016-04-01 2019-05-03 中南大学湘雅医院 一种膜蛋白ENTs跨膜转运ODNs的试剂盒及方法
JP6879677B2 (ja) 2016-05-26 2021-06-02 株式会社クボタ 作業車
US10899741B2 (en) 2016-11-14 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
MX2022012558A (es) * 2020-04-07 2023-02-22 iTeos Belgium SA Derivados de diaminas macrocíclicas como inhibidores de ent para el tratamiento de cánceres y combinación de estos con antagonistas del receptor de adenosina.
CN118026877A (zh) * 2024-02-19 2024-05-14 深圳菲斯生物科技有限公司 一种甲氧氯普胺ep杂质f的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701396D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Compounds
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2004060902A2 (en) 2002-12-31 2004-07-22 John K Buolamwini Novel nucleoside transport inhibitors
JPWO2004101593A1 (ja) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
WO2005063788A1 (ja) * 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
EP1903960A2 (en) * 2005-07-15 2008-04-02 Children's Hospital Medical Center Apparatus for minimally invasive posterior correction of spinal deformity
TW200804393A (en) 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use

Also Published As

Publication number Publication date
JP5369108B2 (ja) 2013-12-18
CN101855224A (zh) 2010-10-06
JP2011503147A (ja) 2011-01-27
ES2569511T3 (es) 2016-05-11
TW200936593A (en) 2009-09-01
US8263592B2 (en) 2012-09-11
KR101598136B1 (ko) 2016-02-29
HK1146722A1 (en) 2011-07-08
AU2008322960A1 (en) 2009-05-22
CA2704423A1 (en) 2009-05-22
BRPI0820642A2 (pt) 2020-08-11
WO2009062990A3 (en) 2009-09-24
IL205710A0 (en) 2010-11-30
EA017215B1 (ru) 2012-10-30
CL2008003383A1 (es) 2010-02-05
KR20100089088A (ko) 2010-08-11
EP2209790B1 (en) 2016-02-17
AU2008322960B2 (en) 2013-02-07
BRPI0820642B1 (pt) 2021-05-25
EA201070599A1 (ru) 2010-12-30
IL205710A (en) 2013-07-31
TWI437000B (zh) 2014-05-11
WO2009062990A2 (en) 2009-05-22
EP2209790A2 (en) 2010-07-28
US20100280025A1 (en) 2010-11-04
PA8803401A1 (es) 2009-06-23
CA2704423C (en) 2017-01-10
CN101855224B (zh) 2012-11-28
AR069304A1 (es) 2010-01-13

Similar Documents

Publication Publication Date Title
WO2009062990A3 (en) Equilibrative nucleoside transporter ent1 inhibitors
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
CY1110342T1 (el) Κανναβινοειδεις αγωνιστες βενζιμιδαζολης που φερουν μια υποκατεστημενη ετεροκυκλικη ομαδα
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX2009000884A (es) Derivados de piridizinona.
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
NI201000033A (es) Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
GEP20146197B (en) New compounds
ATE533762T1 (de) Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
WO2009071631A3 (en) Dibenzoazepine and dibenzooxazepine trpa1 agonists
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
NZ590650A (en) Buprenorphine analogs
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
ATE520668T1 (de) Sigmarezeptor-inhibitoren
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
MX2011013869A (es) Agentes antihelminticos y su uso.
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
SI2201002T1 (sl) Antagonisti 5-ht7 receptorja